ReShape Accounts Payable from 2010 to 2025

RSLS Stock  USD 3.77  0.08  2.08%   
ReShape Lifesciences Accounts Payable yearly trend continues to be comparatively stable with very little volatility. Accounts Payable will likely drop to about 1.3 M in 2025. Accounts Payable is the amount ReShape Lifesciences owes to suppliers or vendors for products or services received but not yet paid for. It represents ReShape Lifesciences' short-term liabilities. View All Fundamentals
 
Accounts Payable  
First Reported
2005-12-31
Previous Quarter
M
Current Value
2.1 M
Quarterly Volatility
1.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check ReShape Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ReShape Lifesciences' main balance sheet or income statement drivers, such as Interest Expense of 22.2 K, Other Operating Expenses of 26.5 M or Total Operating Expenses of 24.6 M, as well as many indicators such as Price To Sales Ratio of 0.19, Dividend Yield of 0.0 or PTB Ratio of 0.24. ReShape financial statements analysis is a perfect complement when working with ReShape Lifesciences Valuation or Volatility modules.
  
Check out the analysis of ReShape Lifesciences Correlation against competitors.
For more information on how to buy ReShape Stock please use our How to Invest in ReShape Lifesciences guide.

Latest ReShape Lifesciences' Accounts Payable Growth Pattern

Below is the plot of the Accounts Payable of ReShape Lifesciences over the last few years. An accounting item on the balance sheet that represents ReShape Lifesciences obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of ReShape Lifesciences are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. It is the amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities. ReShape Lifesciences' Accounts Payable historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ReShape Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Accounts Payable10 Years Trend
Slightly volatile
   Accounts Payable   
       Timeline  

ReShape Accounts Payable Regression Statistics

Arithmetic Mean1,502,614
Geometric Mean946,577
Coefficient Of Variation86.90
Mean Deviation1,006,574
Median1,312,000
Standard Deviation1,305,838
Sample Variance1.7T
Range4.1M
R-Value0.61
Mean Square Error1.2T
R-Squared0.37
Significance0.01
Slope166,723
Total Sum of Squares25.6T

ReShape Accounts Payable History

20251.3 M
20241.9 M
20231.7 M
20221.9 M
20213.5 M
20203.7 M
20194.3 M

About ReShape Lifesciences Financial Statements

ReShape Lifesciences shareholders use historical fundamental indicators, such as Accounts Payable, to determine how well the company is positioned to perform in the future. Although ReShape Lifesciences investors may analyze each financial statement separately, they are all interrelated. The changes in ReShape Lifesciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on ReShape Lifesciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Accounts Payable1.9 M1.3 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for ReShape Stock Analysis

When running ReShape Lifesciences' price analysis, check to measure ReShape Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ReShape Lifesciences is operating at the current time. Most of ReShape Lifesciences' value examination focuses on studying past and present price action to predict the probability of ReShape Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ReShape Lifesciences' price. Additionally, you may evaluate how the addition of ReShape Lifesciences to your portfolios can decrease your overall portfolio volatility.